Ditchcarbon
  • Customers
  1. Organizations
  2. Kyowa Kirin
Public Profile
Pharmaceutical Preparation Manufacturing
JP
updated 2 months ago

Kyowa Kirin

Company website

Kyowa Kirin Co., Ltd., a prominent biopharmaceutical company, is headquartered in Tokyo, Japan (JP). Founded in 1949, the company has established a strong presence in the global healthcare industry, focusing on innovative drug development in areas such as oncology, nephrology, and immunology. Kyowa Kirin is renowned for its unique biologics and small molecule therapies, which leverage advanced technologies to address unmet medical needs. The company has achieved significant milestones, including the successful launch of several key products that have positioned it as a leader in the biopharmaceutical sector. With a commitment to research and development, Kyowa Kirin continues to expand its operational footprint across major regions, including North America, Europe, and Asia, solidifying its market position through strategic partnerships and a robust pipeline of therapeutic solutions.

DitchCarbon Score

How does Kyowa Kirin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

76

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

29

Industry Benchmark

Kyowa Kirin's score of 76 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.

87%

Let us know if this data was useful to you

Kyowa Kirin's reported carbon emissions

In 2024, Kyowa Kirin reported significant carbon emissions, with Scope 1 emissions totalling approximately 16,133,000 kg CO2e and Scope 2 emissions at about 2,087,000 kg CO2e globally. The company also disclosed Scope 3 emissions, which included approximately 98,054,000 kg CO2e from purchased goods and services, 57,473,000 kg CO2e from capital goods, and 2,159,000 kg CO2e from downstream leased assets. Kyowa Kirin has set ambitious reduction targets, aiming for a 55% reduction in Scope 1 and Scope 2 emissions by 2030 compared to 2019 levels. This target is part of a broader commitment to reduce Scope 3 emissions by 30% within the same timeframe. Additionally, the company has established an interim target of a 51% reduction in emissions by 2024 compared to 2019 levels. The company is also aligned with the Science Based Targets initiative (SBTi), committing to a 42% reduction in Scope 1 and Scope 2 emissions by 2030 from a 2021 base year, while also focusing on measuring and reducing Scope 3 emissions. Furthermore, Kyowa Kirin is part of the Kirin Group, which has set a long-term goal of achieving net-zero greenhouse gas emissions across its entire value chain by 2050. Overall, Kyowa Kirin's climate commitments reflect a proactive approach to sustainability, with clear targets and a focus on reducing emissions across all scopes.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201920202021202220232024
Scope 1
17,244,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
34,687,000
00,000,000
00,000,000
00,000,000
0,000,000
0,000,000
Scope 3
-
-
-
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Kyowa Kirin's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Kyowa Kirin is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Kyowa Kirin is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Horizon Therapeutics Public Limited Company

IE
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Supernus Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 16 days ago

Allergan Finance, LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Concord Biotech

IN
•
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250918.5
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy